180 Life Sciences Corp. (NASDAQ: ATNF) is thrilled to announce that Professor Jagdeep Nanchahal has been chosen to present at the prestigious Gordon Research Conference on “Physiological and Disease Relevance and Underlying Molecular Properties of Collagens”, from July 9 – 14, 2023 at Colby-Sawyer College in New London, New Hampshire. This is a great opportunity for Professor Nanchahal to share his research and insights with a distinguished group of experts in the field.
Jagdeep Nanchahal, Professor of Hand, Plastic and Reconstructive Surgery at the University of Oxford and chairman of the clinical advisory board of 180 Life Sciences, will be presenting his groundbreaking research findings on Dupuytren’s disease. Through the use of molecular and single cell techniques, his team has identified tumor necrosis factor (TNF) as a potential therapeutic target and have gone on to conduct a pioneering phase 2a and 2b clinical trial. Despite the challenges faced from the emergence of COVID-19, the trial was successful in achieving its primary and secondary endpoints with statistical significance, paving the way for a new era of research and potential treatments for Dupuytren’s disease.
The path to successful development of therapies for new indications is paved with a comprehensive understanding of the disease, meticulous laboratory studies and carefully planned clinical trials. This is a journey that my colleagues and I have already successfully embarked upon in the past, leading to the use of anti-TNF treatments for rheumatoid arthritis. As Executive Co-Chairman of 180 Life Sciences, I’m proud to have been part of this pioneering effort.
Dr. James Woody, CEO of 180 Life Sciences, recently expressed his admiration for the Gordon Research Conferences – internationally renowned gatherings with a history dating back to 1931. Organized by a non-profit, these meetings are designed to spark scientific discussion and progress, as well as foster communities that drive the boundaries of knowledge forward. Each conference is limited to 200 attendees, who are hand-picked by the conference chair. All participants are active members of their respective scientific field, working together to push the boundaries of science.
About 180 Life Sciences Corp.
180 Life Sciences Corp. is leading the way in providing innovative clinical solutions to unmet medical needs. By developing and conducting groundbreaking studies, the company is pioneering the use of anti-TNF (tumor necrosis factor) to treat a variety of inflammatory disorders. This revolutionary approach has the potential to revolutionize the treatment of these conditions and make a real difference in people’s lives.